Research Article

Clinical Characteristics of Metastatic Colorectal Cancer Combined with Gastrointestinal Perforation and Prognostic Value of Circulating Tumor DNA

Hong Yang,1 Dongwen Rong2, and Wenhui Yang3

1Department of Oncology, Inner Mongolia People’s Hospital, Hohhot, Inner Mongolia 010017, China
2Department of Oncology, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China
3Department of Digestive System Oncology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, Shanxi 030032, China

Correspondence should be addressed to Dongwen Rong; jiedw002@163.com and Wenhui Yang; yangwenhui10012@126.com

Received 29 March 2022; Revised 28 April 2022; Accepted 7 May 2022; Published 28 June 2022

Academic Editor: Weiguo Li

Copyright © 2022 Hong Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To explore the clinical characteristics of metastatic colorectal cancer combined with gastrointestinal perforation and the prognostic value of circulating tumor DNA (ctDNA). Methods. A total of 97 patients with metastatic colorectal cancer and gastrointestinal perforation were enrolled as the research objects between February 2016 and January 2019. Their clinicopathological characteristics were statistically analyzed. Patients were divided into the death group (n = 78) and the survival group (n = 19) according to their survival status at 3 years after surgery. The ctDNA level between the two groups was compared. Also, its evaluation value on patient prognosis was analyzed. The survival time in patients with different levels of ctDNA was compared.

Results. The clinical staging was stage T4 in patients with metastatic colorectal cancer combined with gastrointestinal perforation, including 70 cases (72.16%) aged ≥60 years and 27 cases (27.84%) <60 years. There were 61 males (62.89%) and 36 females (37.11%). There were 27 cases (27.84%) with primary site at left colon, 59 cases (60.82%) at right colon and 11 cases (11.34%) at rectum. There were 56 cases (57.73%) with number of metastatic organs ≥2 and 41 cases (42.27%) <2. There were 58 cases (59.79%) treated with VEGF inhibitor before perforation, 40 cases (41.24%) with lung metastasis, 72 cases (74.23%) with liver metastasis, 30 cases (30.93%) with pelvic metastasis, 24 cases (24.74%) with distant lymph node metastasis, 36 cases (37.73%) with obstruction, and 35 cases (36.08%) with diverticulum. According to survival status at 3 years after surgery, patients were divided into the death group (n = 78) and the survival group (n = 19). The level of plasma ctDNA in the death group was higher than that in the survival group (P < 0.05). The area under curve (AUC) of ctDNA for predicting survival of patients was 0.806. According to ctDNA expression, patients were divided into the high expression group (n = 57) and the low expression group (n = 40). The survival rate in the high expression group was lower than that in the low expression group (7.02% (4/57) vs 36.38% (15/40)) (P < 0.001). The median survival time for the two groups was 18.20 and 28.10 months, respectively. Conclusion. Clinical characteristics of metastatic colorectal cancer combined with gastrointestinal perforation include elderly age, obstruction, and diverticulum. The expression of ctDNA has evaluation value for prognosis of patients.

1. Introduction

Metastatic colorectal cancer refers to the tumor cells of colorectal cancer invaded from the primary site to lymphatic vessels and blood vessels, or brought to other tissues and organs by other means, forming the same type of tumor as the primary site tumor [1]. Its prognosis is poor, and it is now believed that tumor invasion and metastasis are the main causes of death in patients with colorectal cancer. Metastatic colorectal cancer combined with gastrointestinal perforation is one of the common clinical emergency abdominal conditions associated with malignancy, which will increase the risk of colorectal peritoneal metastasis (CPM), and can rapidly develop into serious complications such as
peritonitis and infectious shock, increasing perioperative mortality. Therefore, metastatic colorectal cancer combined with gastrointestinal perforation should be treated clinically with aggressive surgical intervention, but the recurrence rate after surgery is still as high as 56.5% [2], and patients still need to continue adjuvant chemotherapy after surgery in order to reduce the risk of recurrence. Circulating tumor DNA (ctDNA) is a small fragment of gene released from solid lesions into the circulation system, mainly derived from tumor metabolism, and the genomic information carried by it is highly consistent with tumor tissue [3]. Relevant studies have pointed out that ctDNA detection can more accurately reflect the epigenetics of tumor-related genes, and then can be used to track the occurrence and development of tumors in the body [4]. At present, many clinical studies [5, 6] have shown that it can be used in the prognostic evaluation of various tumors. However, few studies have been reported on the prognostic evaluation value of ctDNA testing for metastatic colorectal cancer combined with gastrointestinal perforation. Therefore, this study aimed to explore the clinical features of metastatic colorectal cancer complicated with gastrointestinal perforation and the value of ctDNA in evaluating the prognosis of patients so as to provide a reference for the prognostic evaluation of the disease.

2. Materials and Methods

2.1. Clinical Data. 97 patients with metastatic colorectal cancer complicated with gastrointestinal perforation from February 2016 to January 2019 were selected as the research objects. Inclusion criteria are as follows: (1) meet the diagnostic criteria for metastatic colorectal cancer complicated with gastrointestinal perforation [7], and it is pathologically confirmed to be metastatic colorectal cancer; (2) age ≥ 18 years old; (3) normal organ function; (4) voluntary participation in this study after informed consent; (5) those without contraindications to chemotherapy. Exclusion criteria are as follows: (1) patients with neuroendocrine carcinoma and other special types of tumor diseases; (2) patients who died of nondisease causes; (3) patients with other primary malignant tumor diseases; (4) patients with gastrointestinal perforation caused by other reasons; (5) patients with severe blood diseases; (6) pregnant women; (7) those who could not complete the follow-up; (8) those with ineligible or uncollectable baseline plasma specimens.

3. Methods

Collection of clinical data: it used the hospital information system to query the clinical data of the patients, such as age, gender, primary site of the lesion, and treatment with VEGF inhibitor before perforation.

Detection of ctDNA level: 3 ml of fasting venous blood was taken from the patients 1 day before surgery. After anticoagulation treatment, centrifugation was performed at 2000 r/min for 10 min, and the upper plasma was separated, added the cell lysis solution and mixed well, separated the supernatant, added proteinase K, and let it stand at 56°C for 10 minutes after mixing. After the solution was clarified, added anhydrous ethanol and mixed well. After thorough washing, added rinsing solution, by centrifugal rinse twice, added eluate, used Tiangen Biochemical Blood Micro-genomic DNA Extraction Kit to extract plasma ctDNA level, and applied Rado AQT90 FLEX fluorescence quantitative analyzer for detection.

Follow-up methods: outpatient follow-up or telephone follow-up was used to follow up the survival of patients. The follow-up time was 3 years after surgery, or until the time of death of the patients. The patients were divided into the death group and the survival group according to their 3-year survival.

3.1. Observation Indicators. The observation indicators are as follows: (1) statistics of its clinicopathological characteristics; (2) comparison of ctDNA levels in the death and survival group, and analysis of its evaluation value on patients’ prognosis; (3) according to the level of ctDNA, the patients were divided into the high expression group and the low expression group, and the survival time between the two groups was compared, that is, the time from operation to death or the last follow-up time.

3.2. Statistical Processing. The SPSS22 software was used to process the data, the enumeration data were expressed with %, and the χ² test was used to compare differences between groups; the measurement data were expressed as (x ± s) after normality test, and t-test was used to compare differences between groups; the receiver operating characteristic curve (ROC) curve was used to analyze the prognostic value of ctDNA in patients with metastatic colorectal cancer and gastrointestinal perforation. The area under curve (AUC) greater than 0.7 indicated that the index had diagnostic value, and AUC greater than 0.8 indicated that its diagnostic value was high; GraphPad Prism 5 was used for survival curve analysis, using Log-rank χ² was used to compare the survival rates between the two groups. P < 0.05 meant the difference was statistically significant.

4. Results

4.1. Analysis of clinicopathological characteristics of patients with metastatic colorectal cancer and gastrointestinal perforation. The proportion of patients who were more than 60 years old, male, with primary site of the right colon high, is shown in Table 1.

4.2. Comparison of ctDNA Expression between the Death Group and the Survival Group. The patients were divided into the death group (n = 78) and the survival group (n = 19) according to their 3-year survival after operation. The plasma ctDNA level of the death group was (86.59 ± 10.07) ng/mL, which was higher than that of the survival group (78.07 ± 8.52) ng/mL (P < 0.05), is shown in Figure 1.

4.3. The Evaluation Value of ctDNA Expression in Prognosis. The AUC of ctDNA expression in predicting patient survival was 0.806, and the SE (95% CI) was 0.045 (0.718–0.894). The cutoff value was 79.58 ng/mL, as shown in Figure 2.
4.4. Comparison of Survival Time of Patients with Different ctDNA Expressions. According to ctDNA expression, patients were divided into the high expression group (≥79.58 ng/mL) and low expression group (< 79.58 ng/mL). The survival rate of the high expression group was 7.02% (4/57), which was lower than 36.38% (15/40) of the low expression group (Log-rank $\chi^2 = 17.530, P < 0.001$). The median survival time of the two groups was 18.20 and 28.10 months, as shown in Figure 3.

5. Discussion

Colorectal cancer is a common malignant tumor of the digestive system. With the improvement of living conditions, the change of diet structure and the increase of daily pressure, the incidence of colorectal cancer in my country is increasing year by year, which seriously threatens the life and health of patients. Clinical data show that metastatic colorectal cancer is one of the malignancies associated with spontaneous perforation, and the condition can deteriorate sharply with combined peptic perforation, and the mortality rate increases rapidly, which is one of the influential factors affecting poor prognosis, and the analysis of the clinical characteristics of patients with concomitant peptic perforation can help in early diagnosis [8]. Therefore, this study aimed to analyze the clinical characteristics of complicated digestive tract perforation. Relevant studies have pointed out that free or encapsulated gas can be seen in colorectal cancer combined with gastrointestinal perforation during CT scan.

Table 1: Clinicopathological characteristics of patients with metastatic colorectal cancer complicated with gastrointestinal perforation.

| Characteristics                     | Case (%)  |
|-------------------------------------|-----------|
| Age (years)                         |           |
| ≥60                                 | 70 (72.16) |
| < 60                                | 27 (27.84) |
| Primary tumor staging                |           |
| T4a                                 | 55 (56.70) |
| T4b                                 | 42 (43.30) |
| Gender                              |           |
| Male                                | 61 (62.89) |
| Female                              | 36 (37.11) |
| Primary tumor site                  |           |
| Left colon                          | 27 (27.84) |
| Right colon                         | 59 (60.82) |
| Rectum                              | 11 (11.34) |
| Number of metastatic organs         |           |
| ≥2                                  | 56 (57.73) |
| <2                                  | 41 (42.27) |
| Whether the primary tumor was removed|           |
| Yes                                 | 38 (39.18) |
| No                                  | 59 (60.82) |
| Treatment with a VEGF inhibitor prior to perforation |           |
| Yes                                 | 58 (59.79) |
| Combined lung metastases            | 39 (40.21) |
| Combined liver metastases           | 40 (41.24) |
| Combined pelvic metastases          | 72 (74.23) |
| Distant lymph node metastasis       | No        |
| Combined obstruction                | 24 (24.74) |
| Combined diverticula                | 35 (36.08) |

Figure 1: Comparison of ctDNA expression between the death group and the survival group. Two groups were compared, $P < 0.05$.

Figure 2: The evaluation value of ctDNA expression in prognosis.
This study found that 36.08% of patients had diverticulosis, which was slightly higher than the 35.7% in the study carried out by Gao et al. [10], which may be related to the small number of patients included in the study. Metastatic tumors infiltrate the intestinal wall, leading to necrosis and ring control. The progression of the tumor leads to intestinal stenosis and obstruction, which leads to the expansion of the proximal intestinal lumen, and the increase of intestinal wall tension can cause the intestinal wall to rupture. Therefore, many patients have intestinal wall obstruction. The results of this study showed that 57.73% of patients with gastrointestinal perforation had intestinal wall obstruction. This study also found that the proportion of patients with liver metastasis was the highest. The reason is still unknown. The author believes that it may be related to the liver as the main distant metastasis of colorectal cancer. Relevant studies have pointed out that adverse reactions caused by antivascular drug therapy can lead to gastrointestinal perforation [11]. The results of this study showed that the proportion of patients treated with VEGF inhibitor before perforation was higher, further indicating that this regimen may increase the risk of gastrointestinal perforation.

cDNA detection is an emerging technology. Compared with traditional tumor tissue biopsy, it has the advantages of simplicity, ease of operation, and high reproducibility, which can increase patient acceptance [12, 13]. Relevant reports pointed out that cDNA carries certain oncogene information of patients; therefore, cDNA detection can provide important clues for the early diagnosis and efficacy assessment of tumor patients [14, 15]. cDNA is endogenous tumor DNA of the organism, that is, free outside the cells in peripheral blood. It comes from vigorously proliferating tumors or necrosis and apoptosis of tumor cells and carries tumor-specific gene changes [16, 17]. Studies have found that cDNA levels are closely related to the relevant tumor burden. Clinically, it is generally believed that primary tumor, metastases, and circulating tumor cells are the main sources of cDNA [18, 19]. Some studies have also found that the infiltration and metastasis of cancer cells can lead to an increase in the level of cDNA in the body [20, 21], suggesting that it may be related to the prognosis of patients. The results of this study showed that the plasma ctDNA level of the death group was higher than that of the survival group, and the survival rate of the high (ctDNA) expression group was lower than that of the low expression group, indicating that the higher the plasma ctDNA level was, the higher the risk of poor prognosis would be. The results of this study showed that the AUC of ctDNA expression to predict patient survival was 0.806, indicating that ctDNA has predictive value for patient prognosis.

In conclusion, old age, combined obstruction, and diverticulum are the clinical features of metastatic colorectal cancer complicated with gastrointestinal perforation, and the expression of ctDNA has an evaluation value for the prognosis of patients. Since this study was a retrospective analysis and some patients had other underlying diseases, it might interfere with the results of ctDNA examination and affect the final conclusion. Therefore, a multicenter analysis is required in the later stage to verify the research results.

**Data Availability**

The data used and/or analyzed during the current study are available from the corresponding author.

**Ethical Approval**

This study was approved by the ethics committee of our hospital.

**Conflicts of Interest**

The authors declare no conflicts of interest, financial or otherwise.

**References**

[1] H. Hisada, Y. Takahashi, M. Kubota et al., "Clinical and therapeutic features and prognostic factors of metastatic colorectal cancer over age 80: a retrospective study," *BMC Gastroenterology*, vol. 21, no. 1, p. 199, 2021.

[2] T. M. Chen, Y. T. Huang, and G. C. Wang, "Outcome of colon cancer initially presenting as colon perforation and obstruction," *World Journal of Surgical Oncology*, vol. 15, no. 1, p. 164, 2017.

[3] V. Conteduca, D. Wetterskog, E. Scarpi et al., "Circulating tumor DNA fraction (cDNA) as a surrogate predictive biomarker in metastatic castration-resistant prostate cancer (mCRPC)," *Journal of Clinical Oncology*, vol. 37, no. 15_suppl, p. 5039, 2019.

[4] G. Patelli, C. Vaghi, F. Tosi et al., "Liquid biopsy for prognosis and treatment in metastatic colorectal cancer: circulating tumor cells vs circulating tumor DNA," *Targeted Oncology*, vol. 16, no. 3, pp. 309–324, 2021.

[5] A. Campos-Carrillo, J. N. Weitzel, P. Sahoo et al., "Circulating tumor DNA as an early cancer detection tool," *Pharmacology & Therapeutics*, vol. 207, Article ID 107458, 2020.

[6] C. Abbosh, N. J. Birkbak, and C. Swanton, "Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection," *Nature Reviews Clinical Oncology*, vol. 15, no. 9, pp. 577–586, 2018.
[7] E. Van Cutsem, A. Cervantes, R. Adam et al., “ESMO consensus guidelines for the management of patients with metastatic colorectal cancer,” Annals of Oncology, vol. 27, no. 8, pp. 1386–1422, 2016.

[8] P. Song, R. Q. Wang, D. W. Sun, S. J. Liu, L. G. Yao, and S. K. Li, “Clinical outcome analysis of tumor perforation and proximal tumor perforation in colorectal cancer,” Chinese Journal of General Surgery, vol. 34, pp. 622–623, 2019.

[9] Y. H. Shu and J. R. Wen, “Prediction model of intraoperative perforation in ESD for early colorectal cancer and precancerous lesions,” Southwest National Defense Medicine, vol. 30, pp. 829–832, 2020.

[10] H. Gao, Z. L. Wang, T. Xu, Z. H. Wang, Y. S. Cao, and X. T. Zhang, “Retrospective serial analysis of clinicopathological features and prognosis of 14 cases of metastatic colorectal cancer complicated with gastrointestinal perforation,” Journal of Gastroenterology and Hepatology, vol. 31, pp. 56–60, 2022.

[11] P. X. Cao, Y. Z. Shen, Y. Q. Huang, C. X. Jiang, H. Q. Ma, and Z. Y. Wang, "Analysis of clinical features and pathological types of 7408 cases of intestinal lesions detected by colorectal cancer screening." Chinese Journal of Digestive Endoscopy, vol. 35, pp. 630–633, 2018.

[12] B. Pastor, T. André, J. Henriques et al., "Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment," Mol Oncol, vol. 15, no. 9, pp. 2401–2411, 2021.

[13] T. Ma, W. Cao, J. Huang et al., "Utility of circulating tumor DNA in genomic profiling of colorectal cancer with peritoneal metastasis," Journal of Clinical Oncology, vol. 38, no. 15_suppl, Article ID e16057, 2020.

[14] R. Wong, J. Tie, M. Lee et al., "The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with non-specific findings on standard investigations," International Journal of Cancer, vol. 145, pp. 540–547, 2019.

[15] Y. Wang, L. Yang, H. Bao et al., "Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: a prospective cohort study," PLoS Medicine, vol. 18, no. 8, Article ID e1003741, 2021.

[16] X. N. Chen, F. Huang, M. N. Shen, Y. H. Yang, P. L. Wang, and W. Guo, "Comparison of ctDNA gene mutation detection methods and analysis of influencing factors in patients with metastatic colorectal cancer," China Oncology, vol. 31, pp. 192–197, 2021.

[17] J. Y. Li, Y. H. Mao, X. Zhang, Q. Zhou, and L. M. Tan, "Correlation between circulating tumor DNA and metastatic colorectal cancer targeted therapy and drug resistance mechanism," Practical Preventive Medicine, vol. 28, pp. 1450–1454, 2021.

[18] H. Luo, Q. Zhao, W. Wei et al., "Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer," Science Translational Medicine, vol. 12, no. 524, p. 7533, 2020.

[19] J. Tie, J. D. Cohen, S. N. Lo et al., "Prognostic significance of post-surgery circulating tumor DNA in non-metastatic colorectal cancer: individual patient pooled analysis of three cohort studies," International Journal of Cancer, vol. 148, no. 4, pp. 1014–1026, 2021.

[20] B. Wang, S. Wu, F. Huang et al., "Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients," Clinical Chemistry and Laboratory Medicine, vol. 57, no. 10, pp. 1501–1510, 2019.

[21] M. Shepherdson, E. L. Symonds, S. Byrne et al., "Circulating tumor DNA and circumferential resection margin as key prognostic indicators for survival in rectal cancer," Journal of Clinical Oncology, vol. 39, no. 15_suppl, p. 3579, 2021.